Cover Image
Market Research Report

Antivirals Market Analysis: By Type (Hepatitis-C, HIV, Herpes, Hepatitis-B, Influenza & Other Antivirals); By Action (DNA polymerase inhibitors, NS3 Protease inhibitors, Reverse transcriptase inhibitors and Others) A- With Forecast 2019-2024

Published by IndustryARC Product code 416638
Published Content info
Delivery time: 2-3 business days
Back to Top
Antivirals Market Analysis: By Type (Hepatitis-C, HIV, Herpes, Hepatitis-B, Influenza & Other Antivirals); By Action (DNA polymerase inhibitors, NS3 Protease inhibitors, Reverse transcriptase inhibitors and Others) A- With Forecast 2019-2024
Published: December 25, 2018 Content info:

Antivirals are drugs that are used to treat viral infections. While a majority of antivirals are used for treating specific viral infections, there are a few broad-spectrum antivirals to treat other viral infections. As opposed to antibiotics that actually destroy the target pathogen, antivirals only inhibit the growth of the pathogen. Antivirals have the advantage of not causing any side effects and focus on inibiting the replication of the virus. An increase in the disease afflicted population across the globe is one of the major drivers for this market. Apart from this, increasing levels of awareness coupled with the launch of newer and more effective drugs, this market has tremendous opportunities in emerging economies. The antiviral market is expected to grow at a steady and healthy growth rate till the end of the forecast period considered in this report. Expiry of patents is another factor providing opportunities for this market. Factors that include government policies can prove to be challenging factors in this market.

The report also provides an exhaustive overview of antiviral research and development pipeline. A huge amount of research and development is underway to extend the range of antivirals to treat other pathogens. Also, with the tendency of viruses to mutate and become drug resistant, the need of the hour is to develop and refresh the pipeline of antivirals with new therapies. A section on patent analysis is also included.

Antivirals Market

Antiviral drugs are used in the treatment of HIV, herpes viruses, the hepatitis B and C viruses, and influenza A and B viruses. The global antivirals market is expected to be dominated by HIV antivirals. According to the WHO and UNAIDS estimates, 36.7 million people were living with HIV globally at the end of 2015. In 2015, approximately 2.1 million people became newly infected and 1.1 million died of HIV-related causes.

The Antivirals market can be segmented on the basis of type as:

HIV Antivirals

Hepatitis-C Antivirals

Herpes Antivirals

Influenza Antivirals

Hepatitis-B Antivirals

Other Antivirals

In terms of actions, the Antivirals market has been segmented across the following:

DNA polymerase inhibitors

NS3 Protease inhibitors

Reverse transcriptase inhibitors

The market has been segmented based on the following geographies:

North America

South America



Middle East


Following are just a few of the companies that are operating in the Antivirals market:

GlaxoSmithKline plc

Merck & Co

Johnson and Johnson

Novartis International AG

Gilead Sciences Inc

Table of Contents

Table of Contents

1. Antivirals Market Overview

2. Executive Summary

3. Antivirals Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. Antivirals Market Forces

  • 4.1. Market Drivers
  • 4.2. Market Constraints
  • 4.3. Market Challenges
  • 4.4. Attractiveness of the Antivirals Market
    • 4.4.1. Power of Suppliers
    • 4.4.2. Power of Customers
    • 4.4.3. Threat of New Entrants
    • 4.4.4. Threat of Substitution
    • 4.4.5. Degree of Competition

5. Antivirals Market Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Antivirals Market By Type

  • 6.1. Hepatitis-C antivirals
  • 6.2. HIV antivirals
  • 6.3. Herpes antivirals
  • 6.4. Hepatitis-B antivirals
  • 6.5. Influenza antivirals
  • 6.6. Others

7. Antivirals Market By Actions

  • 7.1. DNA polymerase inhibitors
  • 7.2. NS3 Protease inhibitors
  • 7.3. Reverse transcriptase inhibitors
  • 7.4. Others

8. Antivirals Market By Geography

  • 8.1. Introduction
  • 8.2. Global Study
  • 8.3. Americas
    • 8.3.1. North America
    • 8.3.2. Brazil
    • 8.3.3. Argentina
    • 8.3.4. Others
  • 8.4. Europe
    • 8.4.1. U.K.
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Others
  • 8.5. APAC
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Others
  • 8.6. ROW

9. Antivirals Market Entropy

  • 9.1. New Product Launches
  • 9.2. M&As, Collaborations, JVs and Partnerships

10. Company Profiles

  • 10.1. Novartis AG
  • 10.2. Gilead Sciences Inc.
  • 10.3. Merck
  • 10.4. Johnson and Johnson
  • 10.5. GlaxoSmithKline
  • 10.6. Abbott Laboratories
  • 10.7. AstraZeneca AB
  • 10.8. BoehringerIngelheim Corporation
  • 10.9. Schering-Plough
  • 10.10. Roche

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top